
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5782804/publications.pdf Version: 2024-02-01



LUCA STEADDO ID

#	Article	IF	CITATIONS
1	Cannabidiol Reduces AÎ <sup>2</sup> -Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARÎ <sup>3</sup> Involvement. PLoS ONE, 2011, 6, e28668.	2.5	312
2	Neuroinfection may contribute to pathophysiology and clinical manifestations of COVIDâ€19. Acta Physiologica, 2020, 229, e13473.	3.8	283
3	Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. British Journal of Pharmacology, 2007, 151, 1272-1279.	5.4	235
4	Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation. Gut, 2014, 63, 1300-1312.	12.1	217
5	Targeting neuroinflammation in Alzheimer's disease. Journal of Inflammation Research, 2016, Volume 9, 199-208.	3.5	198
6	Psychiatric face of COVID-19. Translational Psychiatry, 2020, 10, 261.	4.8	169
7	Sigma-1 receptor knockout mice display a depressive-like phenotype. Behavioural Brain Research, 2009, 198, 472-476.	2.2	146
8	New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine. Neuropsychopharmacology, 1995, 13, 177-213.	5.4	138
9	Astrogliopathology. Neuroscientist, 2014, 20, 576-588.	3.5	126
10	Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5Y <i><sup>APP+</sup></i> Cells Through PPARγ Involvement. Phytotherapy Research, 2014, 28, 1007-1013.	5.8	124
11	Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats. Neurobiology of Disease, 2014, 63, 35-47.	4.4	120
12	Suicide in the Early Stage of Schizophrenia. Frontiers in Psychiatry, 2016, 7, 116.	2.6	108
13	Dissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats. Psychopharmacology, 2006, 189, 175-186.	3.1	101
14	Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α. Journal of Neuroinflammation, 2012, 9, 49.	7.2	97
15	Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide. Journal of Cellular and Molecular Medicine, 2011, 15, 2664-2674.	3.6	90
16	Translational potential of astrocytes in brain disorders. Progress in Neurobiology, 2016, 144, 188-205.	5.7	89
17	S100B induces tau protein hyperphosphorylation <i>via</i> Dickopffâ€1 upâ€regulation and disrupts the Wnt pathway in human neural stem cells. Journal of Cellular and Molecular Medicine, 2008, 12, 914-927.	3.6	81
18	Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease. Cell Death and Disease, 2014, 5, e1419-e1419.	6.3	79

#	Article	IF	CITATIONS
19	Opioid system in the medial prefrontal cortex mediates bingeâ€like eating. Addiction Biology, 2014, 19, 652-662.	2.6	77
20	S100B and APP Promote a Gliocentric Shift and Impaired Neurogenesis in Down Syndrome Neural Progenitors. PLoS ONE, 2011, 6, e22126.	2.5	73
21	Opposing Control of Cannabinoid Receptor Stimulation on Amyloid-β-Induced Reactive Gliosis: In Vitro and in Vivo Evidence. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 1144-1152.	2.5	72
22	Antagonism of Sigma-1 Receptors Blocks Compulsive-Like Eating. Neuropsychopharmacology, 2012, 37, 2593-2604.	5.4	72
23	Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes. Frontiers in Neuroscience, 2015, 9, 259.	2.8	72
24	Application of Support Vector Machine on fMRI Data as Biomarkers in Schizophrenia Diagnosis: A Systematic Review. Frontiers in Psychiatry, 2020, 11, 588.	2.6	71
25	The σ-Receptor Antagonist BD-1063 Decreases Ethanol Intake and Reinforcement in Animal Models of Excessive Drinking. Neuropsychopharmacology, 2009, 34, 1482-1493.	5.4	69
26	Withdrawal from chronic, intermittent access to a highly palatable food induces depressive-like behavior in compulsive eating rats. Behavioural Pharmacology, 2012, 23, 593-602.	1.7	69
27	CB1 receptor selective activation inhibits β-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neuroscience Letters, 2006, 404, 342-346.	2.1	68
28	S100B Inhibitor Pentamidine Attenuates Reactive Gliosis and Reduces Neuronal Loss in a Mouse Model of Alzheimer's Disease. BioMed Research International, 2015, 2015, 1-11.	1.9	68
29	Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects. Translational Psychiatry, 2018, 8, 32.	4.8	64
30	Neuroglia in the autistic brain: evidence from a preclinical model. Molecular Autism, 2018, 9, 66.	4.9	63
31	Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimerââ,¬â,,¢s disease. Frontiers in Pharmacology, 2014, 5, 89.	3.5	56
32	Activation of σ-Receptors Induces Binge-like Drinking in Sardinian Alcohol-Preferring Rats. Neuropsychopharmacology, 2011, 36, 1207-1218.	5.4	53
33	Disorganization and real-world functioning in schizophrenia: Results from the multicenter study of the Italian Network for Research on Psychoses. Schizophrenia Research, 2018, 201, 105-112.	2.0	52
34	mTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring rats. Behavioural Brain Research, 2013, 247, 9-16.	2.2	51
35	Altered Waste Disposal System in Aging and Alzheimer's Disease: Focus on Astrocytic Aquaporin-4. Frontiers in Pharmacology, 2020, 10, 1656.	3.5	50
36	Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease: <i>In Vitro</i> and <i>In Vivo</i> Evidence. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-14.	4.0	48

#	Article	IF	CITATIONS
37	Maternal stress, prenatal medical illnesses and obstetric complications: Risk factors for schizophrenia spectrum disorder, bipolar disorder and major depressive disorder. Psychiatry Research, 2019, 271, 23-30.	3.3	46
38	Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models of Alzheimer's Disease. CNS and Neurological Disorders - Drug Targets, 2013, 12, 62-69.	1.4	45
39	Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. Journal of Molecular Medicine, 2007, 85, 1379-1392.	3.9	41
40	Sleep Disturbance in Bipolar Disorder: Neuroglia and Circadian Rhythms. Frontiers in Psychiatry, 2019, 10, 501.	2.6	41
41	Role of astrocytes in major neurological disorders: The evidence and implications. IUBMB Life, 2013, 65, 957-961.	3.4	39
42	Parental bonding, childhood maltreatment and eating disorder psychopathology: an investigation of their interactions. Eating and Weight Disorders, 2020, 25, 577-589.	2.5	39
43	Selective reduction of alcohol drinking in Sardinian alcohol-preferring rats by a sigma-1 receptor antagonist. Psychopharmacology, 2009, 205, 327-335.	3.1	38
44	Palmitoylethanolamide Modulates Inflammation-Associated Vascular Endothelial Growth Factor (VEGF) Signaling via the Akt/mTOR Pathway in a Selective Peroxisome Proliferator-Activated Receptor Alpha (PPAR-î±)-Dependent Manner. PLoS ONE, 2016, 11, e0156198.	2.5	36
45	Rifaximin Improves Clostridium difficile Toxin A-Induced Toxicity in Caco-2 Cells by the PXR-Dependent TLR4/MyD88/NF-κB Pathway. Frontiers in Pharmacology, 2016, 7, 120.	3.5	35
46	Abnormal diurnal patterns of salivary α-amylase and cortisol secretion in acute patients with anorexia nervosa. World Journal of Biological Psychiatry, 2011, 12, 455-461.	2.6	32
47	Astrocyte Function Is Affected by Aging and Not Alzheimer's Disease: A Preliminary Investigation in Hippocampi of 3xTg-AD Mice. Frontiers in Pharmacology, 2019, 10, 644.	3.5	32
48	Impaired glucose metabolism in bipolar patients and response to mood stabilizer treatments. Journal of Affective Disorders, 2019, 245, 174-179.	4.1	31
49	Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by <i>Clostridium difficile</i> toxin A in Cacoâ€2 cells. United European Gastroenterology Journal, 2017, 5, 1108-1115.	3.8	30
50	Deranged emotional and cortisol responses to a psychosocial stressor in anorexia nervosa women with childhood trauma exposure: Evidence for a "maltreated ecophenotype�. Journal of Psychiatric Research, 2018, 104, 39-45.	3.1	30
51	Depressive mood and circadian rhythms disturbances as outcomes of seasonal affective disorder treatment: A systematic review. Journal of Affective Disorders, 2018, 241, 608-626.	4.1	30
52	Sigma-1 receptor mediates acquisition of alcohol drinking and seeking behavior in alcohol-preferring rats. Behavioural Brain Research, 2015, 287, 315-322.	2.2	29
53	Validation of the brief TEMPS-M temperament questionnaire in a clinical Italian sample of bipolar and cyclothymic patients. Journal of Affective Disorders, 2020, 260, 458-462.	4.1	29
54	S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells. Oncology Letters, 2015, 9, 2864-2870.	1.8	28

#	Article	IF	CITATIONS
55	HIV-1 Tat-induced diarrhea evokes an enteric glia-dependent neuroinflammatory response in the central nervous system. Scientific Reports, 2017, 7, 7735.	3.3	26
56	Palmitoylethanolamide Exerts Antiproliferative Effect and Downregulates VEGF Signaling in Caco-2 Human Colon Carcinoma Cell Line Through a Selective PPAR-α-Dependent Inhibition of Akt/mTOR Pathway. Phytotherapy Research, 2016, 30, 963-970.	5.8	25
57	Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of β Amyloid-Induced Astrogliosis <i>In Vitro</i> . CNS and Neurological Disorders - Drug Targets, 2015, 14, 828-837.	1.4	25
58	Looking for a Treatment for the Early Stage of Alzheimer's Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin. International Journal of Molecular Sciences, 2020, 21, 3802.	4.1	24
59	A Randomized Controlled Trial on the Efficacy of a Psychosocial Behavioral Intervention to Improve the Lifestyle of Patients With Severe Mental Disorders: Study Protocol. Frontiers in Psychiatry, 2018, 9, 235.	2.6	23
60	Which factors delay treatment in bipolar disorder? A nationwide study focussed on duration of untreated illness. Microbial Biotechnology, 2021, 15, 1136-1145.	1.7	23
61	A modified adjusting delay task to assess impulsive choice between isocaloric reinforcers in non-deprived male rats: effects of 5-HT2A/C and 5-HT1A receptor agonists. Psychopharmacology, 2012, 219, 377-386.	3.1	22
62	Efficacy of the interpersonal and social rhythm therapy (IPSRT) in patients with bipolar disorder: results from a real-world, controlled trial. Annals of General Psychiatry, 2020, 19, 15.	2.7	22
63	Ultramicronized Palmitoylethanolamide Inhibits NLRP3 Inflammasome Expression and Pro-Inflammatory Response Activated by SARS-CoV-2 Spike Protein in Cultured Murine Alveolar Macrophages. Metabolites, 2021, 11, 592.	2.9	22
64	Autologous transplantation of intestine-isolated glia cells improves neuropathology and restores cognitive deficits in β amyloid-induced neurodegeneration. Scientific Reports, 2016, 6, 22605.	3.3	21
65	Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients. Neuropsychobiology, 2015, 72, 29-36.	1.9	20
66	HIV-1 Tat-induced diarrhea is improved by the PPARalpha agonist, palmitoylethanolamide, by suppressing the activation of enteric glia. Journal of Neuroinflammation, 2018, 15, 94.	7.2	20
67	Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway. International Journal of Oncology, 2016, 49, 639-645.	3.3	19
68	Current and emerging long-acting antipsychotics for the treatment of schizophrenia. Expert Opinion on Drug Safety, 2021, 20, 771-790.	2.4	19
69	The prokineticin receptor antagonist PC1 rescues memory impairment induced by $\hat{I}^2$ amyloid administration through the modulation of prokineticin system. Neuropharmacology, 2019, 158, 107739.	4.1	18
70	Clinical Severity and Calcium Metabolism in Patients with Bipolar Disorder. Brain Sciences, 2020, 10, 417.	2.3	18
71	Astrocyte: An Innovative Approach for Alzheimer's Disease Therapy. Current Pharmaceutical Design, 2018, 23, 4979-4989.	1.9	17
72	Astroglia, Glutamatergic Transmission and Psychiatric Diseases. Advances in Neurobiology, 2016, 13, 307-326.	1.8	16

#	Article	IF	CITATIONS
73	Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. Biomolecules, 2021, 11, 600.	4.0	16
74	The effects of psychoeducational family intervention on coping strategies of relatives of patients with bipolar I disorder: results from a controlled, real-world, multicentric study. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 977-989.	2.2	15
75	Affective Temperaments and Illness Severity in Patients with Bipolar Disorder. Medicina (Lithuania), 2021, 57, 54.	2.0	15
76	Impaired sensitivity of the hypothalamo-pituitary-thyroid axis to the suppressant effect of dexamethasone in elderly subjects. Psychopharmacology, 1991, 105, 481-484.	3.1	14
77	Clinical correlates of age at onset distribution in bipolar disorder: a comparison between diagnostic subgroups. International Journal of Bipolar Disorders, 2017, 5, 28.	2.2	14
78	Insecure Attachment and Hypothalamus-Pituitary-Adrenal Axis Functioning in People With Eating Disorders. Psychosomatic Medicine, 2018, 80, 710-716.	2.0	14
79	Ethanol-related behaviors in mice lacking the sigma-1 receptor. Behavioural Brain Research, 2016, 297, 196-203.	2.2	13
80	Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. Psychopharmacology, 1988, 96, 223-6.	3.1	12
81	Affective Temperaments and Clinical Course of Bipolar Disorder: An Exploratory Study of Differences among Patients with and without a History of Violent Suicide Attempts. Medicina (Lithuania), 2019, 55, 390.	2.0	12
82	Assessment of de novo copy-number variations in Italian patients with schizophrenia: Detection of putative mutations involving regulatory enhancer elements. World Journal of Biological Psychiatry, 2019, 20, 126-136.	2.6	12
83	Psychoeducational Intervention for Perinatal Depression: Study Protocol of a Randomized Controlled Trial. Frontiers in Psychiatry, 2019, 10, 55.	2.6	11
84	Factors associated with lifetime suicide attempts in bipolar disorder: results from an Italian nationwide study. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 359-370.	3.2	11
85	Co-Ultramicronized Palmitoylethanolamide/Luteolin Restores Oligodendrocyte Homeostasis via Peroxisome Proliferator-Activated Receptor-α in an In Vitro Model of Alzheimer's Disease. Biomedicines, 2022, 10, 1236.	3.2	10
86	Correlates of current rapid-cycling bipolar disorder: Results from the Italian multicentric RENDiBi study. European Psychiatry, 2019, 62, 82-89.	0.2	9
87	Neuroinflammation in Alzheimer's Disease: Friend or Foe?. FASEB Journal, 2020, 34, 1-1.	0.5	9
88	Clinical, genetic, and brain imaging predictors of risk for bipolar disorder in high-risk individuals. Expert Review of Molecular Diagnostics, 2020, 20, 327-333.	3.1	7
89	Postâ€COVIDâ€19 neuropsychiatric syndrome: Is maladaptive glial recovery to blame?. Acta Physiologica, 2021, 233, e13717.	3.8	7
90	Systemic Inflammation and Astrocyte Reactivity in the Neuropsychiatric Sequelae of COVID-19: Focus on Autism Spectrum Disorders. Frontiers in Cellular Neuroscience, 2021, 15, 748136.	3.7	7

#	Article	IF	CITATIONS
91	Antisocial Personality Disorder in Bipolar Disorder: A Systematic Review. Medicina (Lithuania), 2021, 57, 183.	2.0	6
92	Endocannabinoid System as Therapeutic Target of PTSD: A Systematic Review. Life, 2021, 11, 214.	2.4	6
93	Dissociative Symptoms in Bipolar Disorder: Impact on Clinical Course and Treatment Response. Frontiers in Psychiatry, 2021, 12, 732843.	2.6	6
94	Substance use disorders in bipolar disorders: Clinical correlates and treatment response to mood stabilizers. Journal of Affective Disorders, 2022, 300, 326-333.	4.1	6
95	Sex Differences in Bipolar Disorders: Impact on Psychopathological Features and Treatment Response. Frontiers in Psychiatry, 0, 13, .	2.6	6
96	The Italian ICD-11 field trial: clinical utility of diagnostic guidelines for schizophrenia and related disorders. International Journal of Mental Health Systems, 2020, 14, 4.	2.7	5
97	Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression. Frontiers in Psychiatry, 2021, 12, 635502.	2.6	5
98	The ICDâ€11 clinicâ€based field studies are about to be concluded. World Psychiatry, 2017, 16, 331-332.	10.4	4
99	Editorial: Sleep and Mood Disorders. Frontiers in Psychiatry, 2019, 10, 981.	2.6	4
100	Oral Adelmidrol Administration Up-Regulates Palmitoylethanolamide Production in Mice Colon and Duodenum through a PPAR-Î <sup>3</sup> Independent Action. Metabolites, 2022, 12, 457.	2.9	4
101	Effects of Ultramicronized Palmitoylethanolamide on Mitochondrial Bioenergetics, Cerebral Metabolism, and Glutamatergic Transmission: An Integrated Approach in a Triple Transgenic Mouse Model of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2022, 14, .	3.4	4
102	Editorial: Dysmetabolism, Obesity, and Inflammation: Three Prominent Actors in the Drama of Major Neuropsychiatric Disorders. Frontiers in Neuroscience, 2016, 10, 368.	2.8	0
103	Clinical correlates of age at onset distribution in bipolar disorder: a comparison between diagnostic subgroups. European Neuropsychopharmacology, 2016, 26, S431.	0.7	0
104	Thrombocytosis in bipolar disorder: A case report. Bipolar Disorders, 2019, 21, 800-802.	1.9	0
105	Astrocyte-neuron interplay in Alzheimer's disease: evidence from an innovative and promising pharmacological manipulation in a triple transgenic model of the disease. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-65.	0.0	0